Results 231 to 240 of about 13,385,789 (308)

Eligibility for hepatitis B virus (HBV) treatment and prevalence of drug resistance in a Ugandan population cohort

Lumley SF, Kimono B, Mugisha J, Makanga R, Mbonye MK, Ojambo K, Waddilove E, Kent C, Ssengendo B, Ndungutse R, McNaughton AL, Muzaale FN, Seeley J, Quick J, Ocama P, Newton R, Matthews PC.   +16 more
europepmc   +1 more source

Comparative Immunogenicity of a High-Dose Hepatitis B Virus (HBV) Vaccine with Rapid Immunization vs. Standard Schedule in HBV Vaccine-Naïve Adults Aged 25-55 in China. [PDF]

Vaccines (Basel)
Qiu Q, Wang H, Liu X, Pang X, Zhang W.
europepmc   +1 more source

Can Hepatitis B Virus (Hbv) Reactivation Be the Result of a Mild COVID-19 Infection With No Need of Systemic Immunosuppressive Therapy?

, 2023
Braimakis I, Vasileiadi S, Trifylli E, Papadopoulos N, Deutsch M.   +4 more
europepmc   +1 more source

Knowledge of Blood‐Borne Infections Among Secondary School Students in Riyadh, Saudi Arabia

Health Science Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Background Blood‐borne infections remain a major global public health concern. Adolescents may encounter preventable exposure risks, making adequate knowledge of transmission and prevention important. This study assessed knowledge of blood‐borne infections and associated sociodemographic factors and explored the association between previous ...
Fatimah Alabdulkareem, Homood A. Alharbi, Faten Helmy   +2 more
wiley   +1 more source

Prevalence and clinical characterization of hepatitis D virus (HDV) infection among Sudanese patients with hepatitis B virus (HBV): a cross-sectional study. [PDF]

Ann Med Surg (Lond)
Alajab MB, Ibn Auf B, Rafei A, Abdo AE.
europepmc   +1 more source

Predictors of Liver Steatosis Progression Among People Living With HIV in Low‐ and Middle‐Income Countries: A Multicentre Longitudinal Study

Journal of the International AIDS Society, Volume 29, Issue 10, October 2026.
ABSTRACT Introduction Liver steatosis is increasingly recognized as a major comorbidity in people living with HIV (PLWH), with growing evidence suggesting an increased risk of progression to advanced liver disease. We assessed predictors of liver steatosis progression over 36 months in PLWH from low‐ and middle‐income countries.
Marie K. Plaisy, Thierry Tiendrebeogo, Carlotta Mondoka, Mark H. Kuniholm, Rodrigo de Carvalho Moreira, Aggrey Semeere, Rohidas T. Borse, Albert Minga, Gilles Wandeler, Gad Murenzi, Brenda E. Crabtree‐Ramírez, Niharika Samala, Jeremy Ross, Ephrem Mensah, Ardele Mandiriri, Sandra W. Cardoso, Jean Paul Mivumbi, Lameck Diero, Haridas Prasad, Paola Alarcón Murra, Belinda V. Chihota, Suzanne Goodrich, Thida Chanyachukul, Ellen Brazier, Stephany N. Duda, Hugo Perazzo, Antoine Jaquet, the International epidemiology Databases to Evaluate AIDS (IeDEA)   +27 more
wiley   +1 more source

Posttranslational Modifications of p62/SQSTM1 in Health and Disease

MedComm, Volume 7, Issue 10, October 2026.
Schematic illustration of p62 as a posttranslational modifications (PTMs)‐programmed integrator in homeostasis, pathogenesis, and therapeutic targeting. (Left) Homeostasis: In physiological states, p62, through various PTMs such as phosphorylation, ubiquitination, and acetylation, coordinates essential cellular functions.
Weikai Wang, Xin Jiang, Runing Qiu, Chandra Sugiarto Wijaya, Miaoqin Chen, Jin Wang, Liyuan Zhu, Hongchuan Jin, Lifeng Feng   +8 more
wiley   +1 more source

Mucosal‐Associated Invariant T Cells in Health and Disease

MedComm, Volume 7, Issue 10, October 2026.
The roles of MAIT cells in health and disease and their therapeutic applications. In healthy individuals, riboflavin metabolites secreted by commensal bacteria at mucosal sites are presented by MR1, leading to the activation of MAIT cells. Activated MAIT cells can maintain the barrier integrity of mucosal tissues in a steady state or migrate to the ...
Yu Zhao, Feng‐Mi Ou, Dan Liang, Yang Gao, Qing‐Qing Li, Yi‐Qun Kuang   +5 more
wiley   +1 more source

miRNA-221: A Potential Biomarker of Progressive Liver Injury in Chronic Liver Disease (CLD) due to Hepatitis B Virus (HBV) and Nonalcoholic Fatty Liver Disease (NAFLD). [PDF]

Int J Hepatol
Sutradhar PR, Sultana N, Nessa A.
europepmc   +1 more source

A Distinct Immune Signature Characterizes Cirrhosis in Ethiopian Individuals With Chronic HBV Infection

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 7, Page 951-964, October 2026.
Cirrhosis patients with untreated HBV in Ethiopia exhibit a distinct immune profile marked by depletion of NK cells, B cells, and T cells, alongside an expanded CD38+HLA‐DR+ CD8 T‐cell population. ABSTRACT Background and Aims The immune cell phenotype of African patients living with chronic hepatitis B virus (HBV) infection is rarely described, despite
Julia MacLeod, Fikadu G. Gudissa, Asiya Jeylan, Nega Berhe, Hailemichael Desalegn, Lasse Rossvoll, Asgeir Johannessen, Niklas K. Björkström, Dag Henrik Reikvam, Annika Niehrs   +9 more
wiley   +1 more source